Cue Biopharma Inc V.CUE

Primary Symbol: CUE

Healthcare Biotechnology

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

NDAQ:CUE - Post by User

Cue Biopharma Inc > Germany to Drop Nuclear Power by 2022

<< Previous

Bullboard Posts

Next >>

Comment by Salvadoralon May 30, 2011 10:18pm

222 Views

Post# 18647252

RE: Germany to Drop Nuclear Power by 2022

That's funny, drop nuclear power, not a chance. What's the alternative? There is no feasable alternative. Coal is too dirty, the rest of the world is reducing green house gas. NG, same situation. Wind, solar or tidal are just piece meal solutions? The german people are radical folks but the first time someone flips a light switch and nothing happens the political wind will change. Nuclear is the only answer. Salvadoral

<< Previous

Bullboard Posts

Next >>

Yukon agency detects cyanide near Victoria Gold's Eagle mine